192 related articles for article (PubMed ID: 37211170)
1. Role of microglial metabolic reprogramming in Parkinson's disease.
Huang ZP; Liu SF; Zhuang JL; Li LY; Li MM; Huang YL; Chen YH; Chen XR; Lin S; Ye LC; Chen CN
Biochem Pharmacol; 2023 Jul; 213():115619. PubMed ID: 37211170
[TBL] [Abstract][Full Text] [Related]
2. Metabolic reprogramming and polarization of microglia in Parkinson's disease: Role of inflammasome and iron.
Yu H; Chang Q; Sun T; He X; Wen L; An J; Feng J; Zhao Y
Ageing Res Rev; 2023 Sep; 90():102032. PubMed ID: 37572760
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
4. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.
Çınar E; Tel BC; Şahin G
Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436
[TBL] [Abstract][Full Text] [Related]
5. Microglia Mediated Neuroinflammation in Parkinson's Disease.
Isik S; Yeman Kiyak B; Akbayir R; Seyhali R; Arpaci T
Cells; 2023 Mar; 12(7):. PubMed ID: 37048085
[TBL] [Abstract][Full Text] [Related]
6. Microglial MT1 activation inhibits LPS-induced neuroinflammation via regulation of metabolic reprogramming.
Gu C; Wang F; Zhang YT; Wei SZ; Liu JY; Sun HY; Wang GH; Liu CF
Aging Cell; 2021 Jun; 20(6):e13375. PubMed ID: 33964119
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype.
Yildirim-Balatan C; Fenyi A; Besnault P; Gomez L; Sepulveda-Diaz JE; Michel PP; Melki R; Hunot S
J Neuroinflammation; 2024 Feb; 21(1):54. PubMed ID: 38383421
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
9. Advances in NURR1-Regulated Neuroinflammation Associated with Parkinson's Disease.
Al-Nusaif M; Lin Y; Li T; Cheng C; Le W
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555826
[TBL] [Abstract][Full Text] [Related]
10. Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease.
Lv QK; Tao KX; Wang XB; Yao XY; Pang MZ; Liu JY; Wang F; Liu CF
Inflamm Res; 2023 Mar; 72(3):443-462. PubMed ID: 36598534
[TBL] [Abstract][Full Text] [Related]
11. HCH6-1, an antagonist of formyl peptide receptor-1, exerts anti-neuroinflammatory and neuroprotective effects in cellular and animal models of Parkinson's disease.
Wang HL; Cheng YC; Yeh TH; Liu HF; Weng YH; Chen RS; Chen YC; Lu JC; Hwang TL; Wei KC; Liu YC; Wang YT; Hsu CC; Chiu TJ; Chiu CC
Biochem Pharmacol; 2023 Jun; 212():115524. PubMed ID: 37001680
[TBL] [Abstract][Full Text] [Related]
12. A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α-synuclein in a mouse model of Parkinson's disease.
Lu J; Wang C; Cheng X; Wang R; Yan X; He P; Chen H; Yu Z
J Neuroinflammation; 2022 May; 19(1):113. PubMed ID: 35599331
[TBL] [Abstract][Full Text] [Related]
13. Microglial cGAS drives neuroinflammation in the MPTP mouse models of Parkinson's disease.
Ma C; Liu Y; Li S; Ma C; Huang J; Wen S; Yang S; Wang B
CNS Neurosci Ther; 2023 Jul; 29(7):2018-2035. PubMed ID: 36914567
[TBL] [Abstract][Full Text] [Related]
14. Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease.
Zheng T; Zhang Z
Neurochem Int; 2021 Sep; 148():105094. PubMed ID: 34097990
[TBL] [Abstract][Full Text] [Related]
15. Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease.
George S; Rey NL; Tyson T; Esquibel C; Meyerdirk L; Schulz E; Pierce S; Burmeister AR; Madaj Z; Steiner JA; Escobar Galvis ML; Brundin L; Brundin P
Mol Neurodegener; 2019 Aug; 14(1):34. PubMed ID: 31419995
[TBL] [Abstract][Full Text] [Related]
16. The Contribution of Microglia to Neuroinflammation in Parkinson's Disease.
Badanjak K; Fixemer S; Smajić S; Skupin A; Grünewald A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925154
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson's disease models.
Wu J; Xu X; Zheng L; Mo J; Jin X; Bao Y
Int Immunopharmacol; 2021 Oct; 99():108025. PubMed ID: 34364303
[TBL] [Abstract][Full Text] [Related]
18. Activation of HCA2 regulates microglial responses to alleviate neurodegeneration in LPS-induced in vivo and in vitro models.
He D; Fu S; Ye B; Wang H; He Y; Li Z; Li J; Gao X; Liu D
J Neuroinflammation; 2023 Mar; 20(1):86. PubMed ID: 36991440
[TBL] [Abstract][Full Text] [Related]
19. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
20. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.
Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T
Front Immunol; 2021; 12():719807. PubMed ID: 34691027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
